 |
|
Ancient DNA helps UF researchers unearth potential hemophilia therapy
February 28, 2006GAINESVILLE, Fla.-A cut can be life-threatening for people with hemophilia, whose bodies don't produce enough of a protein that prevents prolonged bleeding.
Now University of Florida researchers may be one step closer to finding a safe way to spur production of this missing protein in patients with the most common form of the hereditary bleeding disorder. Using a dormant strand of DNA that has quietly existed in fish for millions of years, the researchers replaced the faulty gene responsible for the disease in neonatal mice, according to findings published online this month in the journal Molecular Therapy.
"The degree to which these patients have problems from hemophilia stems from how much of this protein, factor VIII, is missing," said Bradley Fletcher, M.D., Ph.D., a UF assistant professor of pharmacology and one of the lead authors of the study. "If they have very low levels of it, they have lifelong problems of bleeding, but what's even more problematic for them is they bleed into their joints, knees, hips and ankles, which limits their mobility."
Although hemophiliac mice don't develop some of these more extreme symptoms of the disease, gene therapy prevented profuse bleeding in the animals, the findings show.
More than 18,000 Americans, nearly all men, have hemophilia A, the most common form of the disease, according to the Centers for Disease Control and Prevention. Currently, the only safe treatment for the disorder is a purified form of the protein, but it can cost patients thousands of dollars and its effects don't last long. Scientists have been trying to find a safe way to perform gene therapy in hemophilia patients for years, but problems with the viruses typically used to transport needed genes to their target destinations have stymied their success, Fletcher said.
Researchers usually hide corrective genes inside viruses, which then infect cells. Without the virus to act as a key, the gene would be unable to enter the cell. But viral gene therapy has been associated with medical complications, and a few human patients have died as a result.
Instead, UF researchers used a novel nonviral approach, employing a strand of DNA present in modern-day fish called a transposon to transport the gene directly into the DNA of the mice. Nonviral therapy is thought to be safer, Fletcher said.
Transposons have the natural ability to bounce to different positions in DNA, allowing them to chauffeur genes into the cell. The transposon UF researchers used is one of a few that work in mammals, but until University of Minnesota scientists discovered it in 1997, it had remained hidden in the DNA of fish like trout for 15 million years. Years of mutations in the genetic code had buried the transposon, silencing its ability to issue molecular marching orders.
Fletcher and researchers Li Liu, M.D., Ph.D., an adjunct postdoctoral associate in the department of pharmacology and therapeutics, and Cathryn Mah, a UF assistant professor of pediatric cellular and molecular therapy, used the transposon to inject the gene into endothelial cells, which line blood vessels and other parts of the body. This was unique, Fletcher said, because the liver is generally considered the body's powerhouse for producing the protein needed to keep hemophilia at bay. The study showed that these endothelial cells also can produce enough protein to correct the problem, he said.
"I think endothelial cells are potentially a very important cell to make factor VIII," said Katherine P. Ponder, M.D., an associate professor of medicine and a hemophilia researcher at Washington University in St. Louis. "They're a very attractive cell type to express it."
It also was the first time researchers attempted such an approach on an animal so young. In adult mice, the immune system normally views clotting protein as an invader and rejects it after traditional gene therapy. But UF researchers bypassed this immune response by performing gene therapy on mice within 24 hours of their birth, when their immune systems were still naive and would accept the protein.
This type of approach cannot be used in human babies yet because doctors have no way of gauging how severe hemophilia is in newborns. Patients with mild disease will have fewer problems and the benefits of gene therapy may not outweigh risks to the baby, Fletcher said.
Ponder said she thinks the technique also may prove to share some of the same problems as viral-based gene therapy, potentially activating cells that cause cancer.
Now UF researchers are studying different ways to use the transposon and trying to find a way to overcome the immune attack when performing gene therapy on adult animals.
"I don't think the research is done," Mah said. "But this is definitely a step forward for hemophilia gene therapy."
University of Florida
Although hemophiliac mice don't develop some of these more extreme symptoms of the disease, gene therapy prevented profuse bleeding in the animals, the findings show.
More than 18,000 Americans, nearly all men, have hemophilia A, the most common form of the disease, according to the Centers for Disease Control and Prevention. Currently, the only safe treatment for the disorder is a purified form of the protein, but it can cost patients thousands of dollars and its effects don't last long. Scientists have been trying to find a safe way to perform gene therapy in hemophilia patients for years, but problems with the viruses typically used to transport needed genes to their target destinations have stymied their success, Fletcher said.
Researchers usually hide corrective genes inside viruses, which then infect cells. Without the virus to act as a key, the gene would be unable to enter the cell. But viral gene therapy has been associated with medical complications, and a few human patients have died as a result.
Instead, UF researchers used a novel nonviral approach, employing a strand of DNA present in modern-day fish called a transposon to transport the gene directly into the DNA of the mice. Nonviral therapy is thought to be safer, Fletcher said.
Transposons have the natural ability to bounce to different positions in DNA, allowing them to chauffeur genes into the cell. The transposon UF researchers used is one of a few that work in mammals, but until University of Minnesota scientists discovered it in 1997, it had remained hidden in the DNA of fish like trout for 15 million years. Years of mutations in the genetic code had buried the transposon, silencing its ability to issue molecular marching orders.
Fletcher and researchers Li Liu, M.D., Ph.D., an adjunct postdoctoral associate in the department of pharmacology and therapeutics, and Cathryn Mah, a UF assistant professor of pediatric cellular and molecular therapy, used the transposon to inject the gene into endothelial cells, which line blood vessels and other parts of the body. This was unique, Fletcher said, because the liver is generally considered the body's powerhouse for producing the protein needed to keep hemophilia at bay. The study showed that these endothelial cells also can produce enough protein to correct the problem, he said.
"I think endothelial cells are potentially a very important cell to make factor VIII," said Katherine P. Ponder, M.D., an associate professor of medicine and a hemophilia researcher at Washington University in St. Louis. "They're a very attractive cell type to express it."
It also was the first time researchers attempted such an approach on an animal so young. In adult mice, the immune system normally views clotting protein as an invader and rejects it after traditional gene therapy. But UF researchers bypassed this immune response by performing gene therapy on mice within 24 hours of their birth, when their immune systems were still naive and would accept the protein.
This type of approach cannot be used in human babies yet because doctors have no way of gauging how severe hemophilia is in newborns. Patients with mild disease will have fewer problems and the benefits of gene therapy may not outweigh risks to the baby, Fletcher said.
Ponder said she thinks the technique also may prove to share some of the same problems as viral-based gene therapy, potentially activating cells that cause cancer.
Now UF researchers are studying different ways to use the transposon and trying to find a way to overcome the immune attack when performing gene therapy on adult animals.
"I don't think the research is done," Mah said. "But this is definitely a step forward for hemophilia gene therapy."
University of Florida
Hemophilia Current Events and Hemophilia News RSSResearch highlights need to address hemophilia in developing world
When modern medicine finds a way to treat a medical condition, people often think that the problem is solved. But we also have to find ways to get that treatment into the hands of those who need it.
Governor recognizes stem cell research at Einstein
Albert Einstein College of Medicine of Yeshiva University hosted a roundtable discussion on stem cell research with New York Governor David A. Paterson today.
Jumping genes discovery 'challenges current assumptions'
Jumping genes do most of their jumping, not during the development of sperm and egg cells, but during the development of the embryo itself.
Gene therapy technique thwarts cancer by cutting off tumor blood supply
University of Florida researchers have come up with a new gene therapy method to disrupt cancer growth by using a synthetic protein to induce blood clotting that cuts off a tumor's blood and nutrient supply.
Gene therapy demonstrates benefit in patients with rheumatoid arthritis
Researchers have reported the first clinical evidence that gene therapy reduces symptoms in patients with rheumatoid arthritis, an important milestone for this promising treatment which has endured a sometimes turbulent past.
Redesigned protein accelerates blood clotting
Researchers have made several, subtle changes in the structure of a key protein, dramatically increasing its ability to drive blood clotting, according to a study published in a December edition of the Journal of Thrombosis and Haemostasis.
Mapping a clan of mobile selfish genes
Much of human DNA is the genetic equivalent of e-mail spam: short repeated sequences that have no obvious function other than making more of themselves.
Blood-clotting protein modified for people with hard-to-treat hemophilia
Pathologists at The University of Texas Health Science Center at Houston have developed a chemically modified protein that may help people with a hard-to-treat form of a genetic bleeding disorder known as Hemophilia A.
UF researchers develop improved gene therapy agent
Replacing one amino acid on the surface of a virus that shepherds corrective genes into cells could be the breakthrough scientists have needed to make gene therapy a more viable option for treating genetic diseases such as hemophilia, University of Florida researchers say.
Skin flaps deliver cancer-fighting therapy, ASPS study reveals
Using gene therapy, plastic surgeons have delivered cancer fighting proteins through skin flaps placed on cancerous tumors on rats with a 79 percent reduction in tumor volume.
More Hemophilia Current Events and Hemophilia News Articles
 |
Hemophilia (Genes and Disease) by Michelle Raabe (Author) For many people, bumping into a chair or getting a paper cut means momentary pain, followed by quick healing. But for those with hemophilia, a disease that renders its sufferers unable to clot blood effectively and control hemorrhaging after minor injuries, the healing time can be much more arduous. Resulting from mutations in genes that code for blood proteins necessary for clotting, hemophilia is an ancient, hereditary disease that usually affects males and can be classified as severe, moderate, or mild. "Hemophilia", a detailed and easy-to-read guide filled with informative stories of the disease's history, strives to educate readers about the science of hemophilia, while emphasizing how people with this disease can live full and productive lives. The development and technology behind... |
 |
Textbook of Hemophilia by Christine A. Lee (Editor), Erik E. Berntorp MD PhD (Editor), W. Keith Hoots MD (Editor), Louis M. Aledort MD (Editor) The only up-to-date definitive reference source on hemophilia This book is an invaluable resource that provides an overview of all aspects of the care of patients with haemophilia. Covering how to assess both bleeding children and adults, Haemophilia A and B, molecular basis of the disease, the role of factors in coagulation, epidemiology, pharmacokinetics, and treatment of inhibitors. There will also be a section on musculoskeletal aspects of haemophilia as well as newer developments such as gene therapy and rare bleeding disorders. Textbook of Hemophilia is ideal for: Why Buy This... |
|
World Federation of Hemophilia Membership by World Federation of Hemophilia | |
 |
Blood Saga: Hemophilia, AIDS, and the Survival of a Community, Updated Edition With a New Preface by Susan Resnik (Author) For thousands of years boys known as "bleeders" faced an early, painful death from hemophilia. Dubbed "the Royal Disease" because of its identification with Queen Victoria, the world's most renowned carrier, hemophilia is a genetic disease whose sufferers had little recourse until the mid-twentieth century. In the first book to chronicle the emergence and transformation of the hemophilia community, Susan Resnik sets her story within our national political landscapewhere the disease is also a social, psychological, and economic experience. Blood Saga includes many players and domains: men with hemophilia and their families, medical personnel, science researchers, and the author herself, who was Director of Education of the National Hemophilia Foundation in the ... |
 |
Understanding Hemophilia Part of the award winning public television series Healthy Body/Healthy Mind. Bleeding due to a cut or wound can be a little scary at times, especially if your child is a hemophiliac. Hemophiliacs lack specific blood proteins known as clotting factors that our bodies need to control bleeding following an injury. Fortunately, there is far more hope than ever before for these young patients. This episode features individuals with hemophilia who are successfully managing the disease in a manner that allows them to enjoy active and productive lives. This product is manufactured on demand using DVD-R recordable media. Amazon.com's standard return policy will apply. |
|
An Unexpected Life Living with Hemophilia 58 minute documentary that captures a slice of living history and creates and inspirational message about surviving with hemophilia and related bleeding disorders. | |
 |
Hemophilia and Your Child: Interactive Education and Support for Parents by Bayer, Inc. Healthcare Division Hemophilia and Your Child is an interactive program designed to provide education and support to parents raising children with hemophilia. This CD-Rom has been developed by a group of hemophilia nurses, physiotherapists, physicians, parents, and Bayer in collaboration with the Canadian Hemophilia Society. This program integrates a variety of learning styles and adapts to the user's pace and interests. The content was developed with the help of the advisory board and a team of medical researches and writers. A feature of this CD is video clips of parents discussing the challenges of living with hemophilia, providing realistic peer education. |
 |
Ft. Hemophilia Drive-In Eight Lanes To Nowhere Bill Frenzer and Ogden Edsl (Primary Contributor) |
 |
The Gift of Experience: Conversations About Hemophilia by Laura Gray (Author), Christine Chamberlain (Author) "The Gift of Experience" captures the lives and perspectives of twenty-one men, born with hemophilia, and their caregivers, in ways that other resources have failed to do. In vital and personal stories, their accounts capture the impact of the dramatic advances in the treatment of the disease as well as the challenges of chronic pain and joint damage. The conversations also include discussions of the HIV and hepatitis C infections resulting from the tainted blood supply between the late 1960s and the mid-1980s. Laura Gray and Christine Chamberlain have done a tremendous job weaving these oral histories into a narrative that allows their subjects to speak for themselves. "The Gift of Experience" is a 'must read' for anyone interested in the illness and disability experiences of people... |
|
Hemophilia Awareness Ribbon Mouse Pad by MyHeritageWear.com |
| © 2009 BrightSurf.com |